DESTINY-Breast03 Phase 3 Study Results

Safety Summary No dose limiting toxicities Patients, n (%) Any grade AEs Grade 3/4 Any grade treatment-related AEs Grade 3/4 Dose adjustments Dato-DXd dose reduction a Dato-DXd dose delay Durvalumab dose delay Serious AEs AEs leading to death AEs leading to discontinuation of all treatments Data cutoff: November 15, 2021 ESMO BC 2022 #166 Mini Oral Dato-DXd + D N=29 29 (100) 8 (28) 27 (93) 8 (28) 4 (14) 1 (3) 4 (14) 5 (17) 1 (3)b 2 (7) Daiichi-Sankyo a All 4 Dato-DXd dose reductions were due to stomatitis. b One patient died due to hypotension unrelated to treatment. c Includes 1 case of anaphylactic reaction and 1 case of troponin increase. 12 79

View entire presentation